Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a)

Area of Science:

• Cardiology
• Metabolic Disorders
• Vascular Medicine

Background:

• Lipoprotein(a) (Lp(a)) is a significant risk factor for premature coronary artery disease.
• Standard hypolipidemic diets and drug therapies are insufficient for controlling elevated Lp(a) levels.
• Lipid apheresis is currently the sole effective method for reducing Lp(a) in patients with progressive cardiovascular disease (CVD).

Purpose of the Study:

• To evaluate the efficacy of lipid apheresis in reducing vascular events in patients with elevated Lp(a) and progressive CVD.
• To provide evidence supporting the use of lipid apheresis as a treatment of choice for specific patient groups.

Main Methods:

• A prospective, randomized, controlled trial was designed.
• The study aimed to test the hypothesis that lipid apheresis decreases vascular events.

Main Results:

• Lipid apheresis was accepted as a treatment of choice in Germany for patients with Lp(a) levels > 60 mg/dl and progressive CVD.
• A controlled trial was mandated to prove the efficacy of lipid apheresis for this indication.

Conclusions:

• Lipid apheresis is a proven therapeutic regimen for effectively lowering Lp(a) levels.
• The study provides evidence for the reduction of vascular events through lipid apheresis in high-risk patients.